Risk factors

Trevi Therapeutics (TRVI) risk factors

Item 1A of every Trevi Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open TRVI in Gloomberb →
  • FY2025 10-K risk factors

    85 risks, 12 new, 12 dropped, 28 reworded since the prior year. Trevi highlights risks around clinical trials for lead candidate Haduvio, shifting regulatory and tax policies, and patent protections.

    Filed Mar 17, 2026
  • FY2024 10-K risk factors

    85 risks. Trevi Therapeutics faces significant ongoing net losses, with an accumulated deficit of $287.0 million as of December 31, 2024. The company depends entirely on the clinical success and commercialization of its sole lead product candidate, Haduvio. Financial runway is projected to extend only into the second half of 2026.

    Filed Mar 18, 2025